Re: Johansson E, Giovannitti M, Mezzetti M, et al. Cost-effectiveness analysis of baricitinib versus dupilumab for moderate to severe atopic dermatitis: an Italian healthcare system perspective. J Med Econ. 2023;26(1):1155-1166

MeSH terms

• Antibodies, Monoclonal, Humanized* / economics
• Antibodies, Monoclonal, Humanized* / therapeutic use
• Azetidines* / economics
• Azetidines* / therapeutic use
• Cost-Benefit Analysis*
• Cost-Effectiveness Analysis
• Dermatitis, Atopic* / drug therapy
• Dermatitis, Atopic* / economics
• Humans
• Italy
• Purines* / economics
• Purines* / therapeutic use
• Pyrazoles* / economics
• Pyrazoles* / therapeutic use
• Severity of Illness Index
• Sulfonamides* / economics
• Sulfonamides* / therapeutic use